V1rc8 Inhibitors
V1rc8 inhibitors represent a class of chemical compounds designed to interact with a specific biological target known as V1rc8, a nomenclature that typically would be found in a shorthand used within the scientific community to denote a particular protein, enzyme, or receptor. Assuming V1rc8 refers to a valid biological entity, inhibitors for it would function by binding to the active or allosteric sites of this target, thereby modulating its activity. The binding process of such inhibitors is characterized by specificity and affinity, which are critical for the selective inhibition of V1rc8 without affecting similar sites on other proteins or receptors within an organism.
The development of V1rc8 inhibitors would likely involve a rigorous process of chemical synthesis, structure-activity relationship (SAR) studies, and molecular modeling to ensure that these inhibitors are both effective in binding to V1rc8 and exhibit favorable pharmacokinetic properties. The molecular structure of V1rc8 inhibitors could range from small molecules to larger biologics, depending on the nature of the V1rc8 target itself. The design of these compounds is guided by the three-dimensional structure of V1rc8, which would be elucidated through techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. By understanding the topography of the binding site, chemists can tailor functional groups on the inhibitor to interact with corresponding residues on the target, enhancing the stability and duration of the inhibitor-target complex. The inhibition mechanism could either be reversible or irreversible, with reversible inhibitors forming non-covalent interactions with V1rc8, whereas irreversible inhibitors might form covalent bonds, permanently modifying the target.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY294002 prevents phosphorylation and activation of the downstream effector AKT. Since PI3K/AKT signaling is crucial for many cellular processes including survival, its inhibition can lead to reduced activity of proteins such as V1rc8 that rely on PI3K/AKT mediated pathways for their function or expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that prevents mTORC1 activation, Rapamycin consequently inhibits downstream signaling pathways that are essential for protein synthesis and cell growth. Proteins like V1rc8, whose activity may be dependent on these pathways, would see a decrease in their functional activity as a result of this inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK, SB203580 disrupts the MAPK signaling cascade. If V1rc8's function is linked to MAPK pathway activity, inhibition by SB203580 would lead to decreased functionality of V1rc8 due to impaired signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a MEK inhibitor which acts upstream in the MAPK/ERK pathway, potentially reducing the activity of proteins that are regulated by this pathway. If the activity of V1rc8 is modulated by the MAPK/ERK pathway, then PD98059 would result in decreased function of V1rc8. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that specifically blocks the activation of MEK1/2, thereby inhibiting the ERK pathway. If V1rc8 is involved in this pathway, U0126 would lead to a reduction in V1rc8 activity through the suppression of pathway signaling. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A selective NUAK1 inhibitor, which may impact cellular pathways that regulate protein stability and function. If V1rc8 is stabilized or activated by NUAK1, inhibition by WZ4003 would decrease V1rc8 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that causes the accumulation of proteins destined for degradation. If the function of V1rc8 involves proteasome-based degradation pathways, Bortezomib would lead to functional inhibition through the disruption of protein turnover. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
This compound is a reversible proteasome inhibitor that can lead to cell cycle arrest and apoptosis. If V1rc8's function is related to proteasome activity, MG132 would indirectly inhibit its activity by preventing the degradation of regulatory proteins that control V1rc8. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that can inhibit Src family kinases. If V1rc8 is activated by or interacts with Src family kinases, then Dasatinib can lead to decreased functional activity of V1rc8 through its kinase inhibition. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
An Aurora kinase A inhibitor which could impair cell cycle progression and mitosis. If V1rc8's activity is linked to cell cycle regulation or mitosis, Alisertib would inhibit its functional activity by disrupting these processes. | ||||||